Form 4: Mirum Pharmaceuticals Director Equity Grant
Director Equity Grant
Director Saira Ramasastry received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.
Summary
- Director Saira Ramasastry was granted 3,772 stock options with an exercise price of $101.
- Director Saira Ramasastry was granted 1,980 restricted stock units (RSUs).
- Both the stock options and RSUs vest on the first anniversary of the grant date (June 15, 2027), or upon the date of the 2027 annual stockholder meeting, whichever occurs first.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Issuance of equity results in minor dilution to existing shareholders.
Risks
- Market volatility affecting the value of the granted equity instruments.
Future Outlook
The equity grants are subject to standard vesting schedules tied to the 2027 annual meeting or the first anniversary of the grant.
Management Comments
- The grants are intended to incentivize the director and align their interests with the company's performance.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.
Comparison to Industry Standards
- The use of a mix of stock options and RSUs is consistent with typical compensation packages for directors in mid-cap pharmaceutical companies.
- Vesting periods tied to annual meetings are a common governance practice to ensure director retention through the annual cycle.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Saira Ramasastry appointed Doug Sheehy, Jody Howe, and Judit Ryvkin as attorneys-in-fact for SEC filings. | 06/10/2026 | Standard administrative procedure to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity on the earlier of June 15, 2027, or the 2027 annual stockholder meeting.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of Power of Attorney execution. |
| 06/15/2026 | Grant date of stock options and restricted stock units. |
| 06/17/2026 | Filing date of the Form 4. |
Keywords
MIRM, Mirum Pharmaceuticals, Director Compensation, Equity Grant, Form 4, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.